Trafficking dynamics of VEGFR1, VEGFR2, and NRP1 in human endothelial cells
Fig 5
Computational model predictions and model validation with trafficking parameters.
A, Updated trafficking parameters for VEGFR1, VEGFR2, and NRP1 based on geometric means of optimized parameter distributions. B, Surface, Rab4a/5a and Rab11a distributions of VEGFR1, VEGFR2 and NRP1 at steady state with the 2022 trafficking parameters. Simulations (“Sim”) and experimental data (“Exp”) of surface VEGFR1, VEGFR2 and NRP1 levels. C, Simulations (lines) and experimental data (dots) for whole-cell VEGFR1, VEGFR2, and NRP1 over time following CHX treatment. D, The schematics show how perturbations–cycloheximide (CHX) and the siRNA Rab knockdowns–are represented in the model. E-F, Changes in surface levels (E) and whole cell levels (F) of VEGFR1, VEGFR2, and NRP1 after Rab4a knockdown, Rab11a knockdown, and double Rab4a/Rab11a knockdown, compared to control (–, no siRNA treatment). The dots in panel F represent experimental results (no change in whole cell VEGFR1, VEGFR2, NRP1 following knockdown treatment) (Fig 2C).